Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sai-Hong Ignatius Ou

Showing results (1-10 of 272) with videos related to

Pageof 28
Sort By:
Drug Design, Development and Therapy|December 14, 2011
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyondSai-Hong Ignatius Ou
Postgraduate Medical Journal|March 20, 2014
Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Sai-Hong Ignatius Ou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
To the editorSai-Hong Ignatius Ou
Journal of Clinical Pathology|May 11, 2013
Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Sai-Hong Ignatius Ou
Expert Review of Anticancer Therapy|February 10, 2012
Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancerSai-Hong Ignatius Ou
Translational Lung Cancer Research|March 26, 2015
Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?Sai-Hong Ignatius Ou
Critical Reviews in Oncology/Hematology|January 20, 2012
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidenceSai-Hong Ignatius Ou
Cancer|April 21, 2015
Darkness before dawn, but will the sun always rise?Sai-Hong Ignatius Ou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2022
In Response to Continuation of Lorlatinib Beyond Progressive DiseaseSai-Hong Ignatius Ou
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2017
Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung CancerSai-Hong Ignatius Ou
Pageof 28

Showing results (1-10 of 272) with videos related to

Sort By:
Pageof 28
Drug Design, Development and Therapy|December 14, 2011
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyondSai-Hong Ignatius Ou
Postgraduate Medical Journal|March 20, 2014
Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Sai-Hong Ignatius Ou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
To the editorSai-Hong Ignatius Ou
Journal of Clinical Pathology|May 11, 2013
Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Sai-Hong Ignatius Ou
Expert Review of Anticancer Therapy|February 10, 2012
Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancerSai-Hong Ignatius Ou
Translational Lung Cancer Research|March 26, 2015
Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?Sai-Hong Ignatius Ou
Critical Reviews in Oncology/Hematology|January 20, 2012
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidenceSai-Hong Ignatius Ou
Cancer|April 21, 2015
Darkness before dawn, but will the sun always rise?Sai-Hong Ignatius Ou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2022
In Response to Continuation of Lorlatinib Beyond Progressive DiseaseSai-Hong Ignatius Ou
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2017
Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung CancerSai-Hong Ignatius Ou
Pageof 28